Prostate Cancer News and Research

RSS
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Further Reading

Tiny biological nanoparticles offer enormous potential for diagnostic and therapeutic applications

Tiny biological nanoparticles offer enormous potential for diagnostic and therapeutic applications

Could a blood test predict how cancer spreads in children?

Could a blood test predict how cancer spreads in children?

Scientists develop new three-in-one blood test that could transform prostate cancer treatment

Scientists develop new three-in-one blood test that could transform prostate cancer treatment

Expert suggests tips for families to help dad take care of his health

Expert suggests tips for families to help dad take care of his health

New biosensor technology could be used in wearable devices to monitor health

New biosensor technology could be used in wearable devices to monitor health

Researchers pinpoint sugar modification in cells that spurs spread of skin cancer

Researchers pinpoint sugar modification in cells that spurs spread of skin cancer

Moffitt researchers develop novel drug that may help combat castration-resistant prostate cancer

Moffitt researchers develop novel drug that may help combat castration-resistant prostate cancer

New diagnostic test uses machine learning to accurately detect aggressive prostate cancer

New diagnostic test uses machine learning to accurately detect aggressive prostate cancer

Southern Research aims to develop new radiosensitizers that may greatly benefit cancer patients

Southern Research aims to develop new radiosensitizers that may greatly benefit cancer patients

Researchers examine link between income level and cancer diagnosis

Researchers examine link between income level and cancer diagnosis

Study: Black and white men with prostate cancer prioritize treatment-related factors differently

Study: Black and white men with prostate cancer prioritize treatment-related factors differently

Study explores effects of androgen deprivation therapy on overall geriatric health

Study explores effects of androgen deprivation therapy on overall geriatric health

New genomic sequencing approach could be first step toward blood tests for early cancer detection

New genomic sequencing approach could be first step toward blood tests for early cancer detection

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

Positive results for AstraZeneca’s PARP inhibitor Lynparza in advanced breast cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Genetic sequencing could help direct treatment for 72% of advanced cancer patients

Genetic sequencing could help direct treatment for 72% of advanced cancer patients

SCIEX to highlight cutting-edge innovations at ASMS 2017

SCIEX to highlight cutting-edge innovations at ASMS 2017

Clinical trial uses small molecule to treat men with incurable prostate cancer

Clinical trial uses small molecule to treat men with incurable prostate cancer

Study finds opioid dependence and overdose rates after urologic surgery

Study finds opioid dependence and overdose rates after urologic surgery

Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer

Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer